Vous n'êtes pas identifié (connexion)

Centre de recherche

JEUDI 30 MARS

Geneviève Asselin et Martin Bussière, UETMIS, CHU de Québec - Université Laval

Conférence

Les bains de chlorhexidine aux soins intensifs : évaluation de l'efficacité et de l'innocuité

Calendrier >

BOTTIN

Paul Toren

Formation
à venir

Aucune offre active

Autres opportunités de carrière
Axe principal
Oncologie
Adresse(s)
Hôtel-Dieu de Québec
10, rue McMahon
0877
Québec (Québec)
CANADA G1R 2J6

Téléphone(s)
+1 418-525-4444, poste 17064
Télécopieur(s)
+1 418-691-5562
Courriel(s)
Paul.Toren@crchudequebec.ulaval.ca

Projet(s) de recherche actif(s)

Aucun projet de recherche à afficher

Publications récentes (voir toutes les publications de ce chercheur)

Toren P, Kim S, Johnson F, Zoubeidi A. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. PLoS ONE,  2016. 11: e0152861
Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Molecular cancer therapeutics,  2015. 14: 59-69
Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. European urology,  2015. 67: 986-90
Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  2015. 33: 1151-6
Toren P, Wong LM, Timilshina N, Alibhai S, Trachtenberg J, Fleshner N, Finelli A. Active surveillance in patients with a PSA >10 ng/mL. Canadian Urological Association journal = Journal de l’Association des urologues du Canada.,  2014. 8: E702-7
Toren P, Zoubeidi A. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). International journal of oncology,  2014. 45: 1793-801
Toren P, Venkateswaran V. Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment. Clinical genitourinary cancer,  2014. 12: 21-6
Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A. Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis,  2014. 3: e115
Toren P, Abouassaly R, Timilshina N, Kulkarni G, Alibhai S, Finelli A. Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus. Urology,  2013. 82: 572-7
Toren PJ, Gleave ME. Novel non-AR therapeutic targets in castrate resistant prostate cancer. Translational andrology and urology,  2013. 2: 265-77
© 2017 Tous droits réservés Centre de recherche du CHU de Québec